Author

Autumn S Mcdonnell

Observed names: A. McDonnell, Autumn McDonnell, Autumn Mcdonnell, Autumn S. McDonnell

Institution: Memorial Sloan Kettering Cancer Center

Observed institution: Memorial Sloan Kettering Cancer Center

OpenAlex ID: A5070010554

Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial

2020 · Dmitriy Zamarin, Sven Walderich, et al. · Journal for ImmunoTherapy of Cancer · 57

Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer

2021 · Beryl L. Manning-Geist, Sushmita B. Gordhandas, et al. · Gynecologic Oncology · 12

Abstract AP27: A PHASE 2 STUDY OF TPIV200/HUFR-1 (A MULTI-EPITOPE FOLATE RECEPTOR ALPHA VACCINE) IN COMBINATION WITH DURVALUMAB IN PATIENTS WITH PLATINUM RESISTANT OVARIAN CANCER

2019 · Dmitriy Zamarin, Oladapo Yeku, et al. · Clinical Cancer Research · 3

38 Phase II study of enzalutamide in androgen receptor positive (AR+) recurrent ovarian cancer: final results

2019 · R. Grisham, D. Giri, et al. · International Journal of Gynecological Cancer · 2

Anti-CD94 monoclonal antibody DR-01 induced response in a refractory primary CNS T-cell lymphoma

2025 · Christian Grommes, Alicia Assini, et al. · Blood

Phase II study of enzalutamide in androgen receptor positive (AR+) recurrent high-grade and low-grade serous ovarian cancer

2020 · R.N. Grisham, D.D. Giri, et al. · Gynecologic Oncology

Works count: 6

Citation count: 74

H-index: 3

I10-index: 2